VTVT Stock Overview
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes.
vTv Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.37|
|52 Week High||US$2.17|
|52 Week Low||US$0.38|
|1 Month Change||100.88%|
|3 Month Change||211.36%|
|1 Year Change||-20.35%|
|3 Year Change||6.20%|
|5 Year Change||-68.65%|
|Change since IPO||-87.42%|
Recent News & Updates
vTv stock soars 18% on $10M equity investment by CinRx Pharma
vTv Therapeutics (NASDAQ:VTVT) is raising $10M via an equity investment by CinPax, a unit of CinRx Pharma. Under the agreements, CinPax acquired ~4.15M class A Common shares of vTv at ~$2.41 apiece. About $6M will be paid in cash at closing, and the remaining $4M payable on Nov. 22. vTv will also issue 1.2M warrants to to CinRx to acquire additional class A shares which become exercisable upon agreed vesting triggers (including FDA approval of TTP399. vTv said it will use CinRx's industry experience to collaborate on the oversight of clinical trials for pharmaceutical products that contain TTP399. VTVT +18.70% to $0.85 premarket July 25
|VTVT||US Biotechs||US Market|
Return vs Industry: VTVT exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: VTVT underperformed the US Market which returned -10.2% over the past year.
|VTVT Average Weekly Movement||13.1%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: VTVT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: VTVT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners.
vTv Therapeutics Inc. Fundamentals Summary
|VTVT fundamental statistics|
Is VTVT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VTVT income statement (TTM)|
|Cost of Revenue||US$12.54m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.19|
|Net Profit Margin||-313.93%|
How did VTVT perform over the long term?See historical performance and comparison